Literature DB >> 25330774

The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.

Stan Pasyk1, Steven Molinski, Saumel Ahmadi, Mohabir Ramjeesingh, Ling-Jun Huan, Stephanie Chin, Kai Du, Herman Yeger, Paul Taylor, Michael F Moran, Christine E Bear.   

Abstract

The major cystic fibrosis causing mutation, F508del-CFTR (where CFTR is cystic fibrosis transmembrane conductance regulator), impairs biosynthetic maturation of the CFTR protein, limiting its expression as a phosphorylation-dependent channel on the cell surface. The maturation defect can be partially rescued by low-temperature (27°C) cell culture conditions or small-molecule corrector compounds. Following its partial rescue, the open probability of F508del-CFTR is enhanced by the potentiator compound, VX-770. However, the channel activity of rescued F508del-CFTR remains less than that of the Wt-CFTR protein in the presence of VX-770. In this study, we asked if there are allosteric effects of F508del on the phosphorylation-regulated R domain. To identify defects in the R domain, we compared the phosphorylation status at protein kinase A sites in the R domain of Wt and F508del-CFTR. Here we show that phosphorylation of Ser-660, quantified by SRM-MS, is reduced in F508del-CFTR. Although the generation of a phosphomimic at this site (substituting aspartic acid for serine) did not modify the maturation defect, it did enhance F508del-CFTR channel function after pharmacological rescue with corrector VX-809, and treatment with the potentiator, VX-770. These findings support the concept that defective phosphorylation of F508del-CFTR partially accounts for its altered channel activity at the cell surface.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Cell biology; Cystic fibrosis; Mass spectrometry; Phosphorylation; Protein kinase A (PKA); Protein misfolding

Mesh:

Substances:

Year:  2014        PMID: 25330774     DOI: 10.1002/pmic.201400218

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  13 in total

Review 1.  Dynamic Protein Interaction Networks and New Structural Paradigms in Signaling.

Authors:  Veronika Csizmok; Ariele Viacava Follis; Richard W Kriwacki; Julie D Forman-Kay
Journal:  Chem Rev       Date:  2016-02-29       Impact factor: 60.622

Review 2.  Trafficking and function of the cystic fibrosis transmembrane conductance regulator: a complex network of posttranslational modifications.

Authors:  Michelle L McClure; Stephen Barnes; Jeffrey L Brodsky; Eric J Sorscher
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-07-29       Impact factor: 5.464

Review 3.  Current insights into the role of PKA phosphorylation in CFTR channel activity and the pharmacological rescue of cystic fibrosis disease-causing mutants.

Authors:  Stephanie Chin; Maurita Hung; Christine E Bear
Journal:  Cell Mol Life Sci       Date:  2016-10-08       Impact factor: 9.261

4.  AC6 is the major adenylate cyclase forming a diarrheagenic protein complex with cystic fibrosis transmembrane conductance regulator in cholera.

Authors:  Andrew Thomas; Yashaswini Ramananda; KyuShik Mun; Anjaparavanda P Naren; Kavisha Arora
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

5.  Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice.

Authors:  Barbara Dhooghe; Charlotte Bouckaert; Arnaud Capron; Pierre Wallemacq; Teresinha Leal; Sabrina Noel
Journal:  Biol Open       Date:  2015-06-19       Impact factor: 2.422

6.  Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity.

Authors:  Firhan A Malik; Anja Meissner; Illya Semenkov; Steven Molinski; Stan Pasyk; Saumel Ahmadi; Hai H Bui; Christine E Bear; Darcy Lidington; Steffen-Sebastian Bolz
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

7.  Attenuation of Phosphorylation-dependent Activation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by Disease-causing Mutations at the Transmission Interface.

Authors:  Stephanie Chin; Donghe Yang; Andrew J Miles; Paul D W Eckford; Steven Molinski; B A Wallace; Christine E Bear
Journal:  J Biol Chem       Date:  2016-12-21       Impact factor: 5.157

8.  Orkambi® and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue.

Authors:  Steven V Molinski; Saumel Ahmadi; Wan Ip; Hong Ouyang; Adriana Villella; John P Miller; Po-Shun Lee; Kethika Kulleperuma; Kai Du; Michelle Di Paola; Paul Dw Eckford; Onofrio Laselva; Ling Jun Huan; Leigh Wellhauser; Ellen Li; Peter N Ray; Régis Pomès; Theo J Moraes; Tanja Gonska; Felix Ratjen; Christine E Bear
Journal:  EMBO Mol Med       Date:  2017-09       Impact factor: 12.137

9.  Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia.

Authors:  Saumel Ahmadi; Zoltan Bozoky; Michelle Di Paola; Sunny Xia; Canhui Li; Amy P Wong; Leigh Wellhauser; Steven V Molinski; Wan Ip; Hong Ouyang; Julie Avolio; Julie D Forman-Kay; Felix Ratjen; Jeremy A Hirota; Johanna Rommens; Janet Rossant; Tanja Gonska; Theo J Moraes; Christine E Bear
Journal:  NPJ Genom Med       Date:  2017-04-14       Impact factor: 8.617

Review 10.  Regulatory Crosstalk by Protein Kinases on CFTR Trafficking and Activity.

Authors:  Carlos M Farinha; Agnieszka Swiatecka-Urban; David L Brautigan; Peter Jordan
Journal:  Front Chem       Date:  2016-01-20       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.